Back to news

Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study

Globe Newswire•17/11/2026•08:00 ET
0

Key Highlights

  • ➤DSMB recommends DUET-AD continue without modification after reviewing safety data from 861 patients
  • ➤Second consecutive positive DSMB recommendation reinforces buntanetap’s safety profile
  • ➤DUET-AD six-month topline results expected in March 2027
  • ➤Database lock for DUET-AD is scheduled for February 8, 2027

Expert Statements

Cheng Fang, Chief Scientific Officer at Annovis

“A second positive recommendation from the DSMB in such a large population further reinforces our confidence in buntanetap’s safety profile”

Cheng Fang, Chief Scientific Officer at Annovis

“This milestone comes at an important time. As we approach the 6-month data readout and prepare for regulatory submission, a demonstrated safety at scale is essential. In March, we will report detailed DUET-AD safety outcomes alongside the 6-month symptomatic results.”

MALVERN, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for DUET-AD, the Company’s pivotal Phase 3 trial in early AD, after the review of the study’s safety data. This 12-month review follows the DSMB’s positive 6-month feedback, which was announced in February 2026.

The DSMB recommended that DUET-AD continue without modification, based on the data accumulated through September 22, 2026, from 861 patients at different stages of dosing.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in